Breast cancer.
This year, manuscripts addressed numerous pertinent breast cancer issues. Notable conclusions from each of the discussed sections suggest that: (a) oral contraceptives do not increase a woman's risk for breast cancer; (b) the vast majority of women with resected premalignant breast lesions do well for prolonged periods after diagnosis regardless of therapy; (c) satisfactory cosmetic results can occur with either lumpectomy, axillary nodal dissection, and radiotherapy or with mastectomy and breast reconstruction; (d) the primary tumor thymidine labeling index can give prognostic information; (e) immunohistochemical methods can accurately measure tumor estrogen receptors; (f) there are multiple hormonal therapies of similar efficacy; (g) two new single agent chemotherapy drugs deserving further investigation are idarubicin and lonidamine; (h) none of several combination chemotherapy regimens is clearly superior to any of the other 'standard' regimens; (i) there is a lack of consensus among the conclusions of recent adjuvant breast cancer consensus conferences held in the United States and London; (j) inflammatory breast cancer patients treated with initial combination chemotherapy consistently appear to have improved relapse-free and overall survivals when compared to historical controls; and (k) the prognosis in locally recurrent breast cancer patients is better in those previously treated with lumpectomy and irradiation when compared to those previously treated with mastectomy.
Loprinzi
C L
CL
Carbone
P P
PP
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D005260:Female; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008403:Mass Screening; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy; D011230:Precancerous Conditions / Q000628:therapy; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis
D000970:Antineoplastic Agents; D006728:Hormones; D011960:Receptors, Estrogen